Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 348.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,788 shares of the company's stock after purchasing an additional 29,355 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.07% of Astrana Health worth $1,191,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB increased its holdings in Astrana Health by 4.7% in the fourth quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company's stock worth $281,000 after buying an additional 400 shares during the last quarter. KBC Group NV acquired a new position in Astrana Health in the third quarter worth approximately $70,000. Quarry LP acquired a new position in Astrana Health in the third quarter worth approximately $77,000. Quest Partners LLC bought a new stake in Astrana Health during the third quarter worth approximately $133,000. Finally, Linden Thomas Advisory Services LLC boosted its position in Astrana Health by 23.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 15,247 shares of the company's stock worth $481,000 after purchasing an additional 2,883 shares during the period. Institutional investors and hedge funds own 52.77% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. Robert W. Baird decreased their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Macquarie raised Astrana Health to a "hold" rating in a research report on Monday, December 16th. Truist Financial decreased their target price on Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Stifel Nicolaus decreased their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research report on Thursday, February 20th. Finally, Bank of America decreased their target price on Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Astrana Health currently has an average rating of "Moderate Buy" and an average target price of $56.17.
View Our Latest Stock Analysis on ASTH
Astrana Health Stock Performance
Shares of ASTH traded up $0.07 during mid-day trading on Friday, hitting $30.89. The company's stock had a trading volume of 679,468 shares, compared to its average volume of 255,139. Astrana Health, Inc. has a one year low of $23.12 and a one year high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The firm has a market capitalization of $1.55 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The stock's 50-day moving average is $33.97 and its two-hundred day moving average is $42.52.
Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. As a group, sell-side analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current year.
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
